Medtronic (NYSE:MDT) Upgraded by Mizuho to "Strong-Buy" Rating

robot
Abstract generation in progress

Mizuho upgraded Medtronic (NYSE:MDT) to a “strong-buy” rating, contributing to a “Moderate Buy” consensus among analysts with a $111.05 price target. The upgrade follows Medtronic’s beat on Q3 earnings expectations and positive FY2026 guidance, driven by strong demand for heart devices. Despite overall positive sentiment from some analysts highlighting growth potential in cardiovascular and robotics, others express mixed views, trimming price targets due to legal and competitive challenges.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский язык
  • Français
  • Deutsch
  • Português (Portugal)
  • ภาษาไทย
  • Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)